Friday, May 28, 2021

Zydus Cadila Q4 net up 73% to Rs 679 cr, total income up a marginal 3%

During Q4FY21, firm launched Virafin to treat moderate infections in adult Covid-19 patients. Its ZyCoV-D plasmid DNA vaccine is at an advanced stage of Phase-3 trials

from Today's Paper https://ift.tt/3vtM0lA
via
By at
Labels: ,

No comments:

Post a Comment

If you have any doubts please let me know!

Subscribe to: Post Comments (Atom)

India's low score on GVC a starting point for recovery from pandemic: AIIB

India rated 7.4 percentage points below the average global value chain participation rate for emerging economies from Today's Paper ht...